Proteome Sciences (PRM) AI Stock Analysis

• Market Cap: £9.62M
• Dividend Yield: N/A
• Average Volume (3M): 342.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.11
• Revenue Growth: -2.80%
• EPS Growth: -38.55%
• Country: UK
• Employees: 36
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.01
• Shares Outstanding: 295,182,040
• 10 Day Avg. Volume: 197,032
• 30 Day Avg. Volume: 342,812
• PEG Ratio: 0.04
• Price to Book (P/B): -2.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Proteome Sciences' stock score is significantly impacted by its financial instability, characterized by declining revenues, negative equity, and poor cash flow management. These challenges weigh heavily on the score, despite the company's positive corporate events that suggest future growth potential. The technical analysis indicates a bearish trend, and the valuation metrics reflect ongoing financial difficulties, further contributing to a low overall score.

Proteome Sciences Business Overview & Revenue Model

Company Description

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

How the Company Makes Money

Proteome Sciences generates revenue through a mix of service contracts and licensing agreements. The company offers contract research services in proteomics, leveraging mass spectrometry technology to support pharmaceutical companies in drug discovery and development. This involves providing detailed protein analysis and biomarkers that help in understanding disease mechanisms and treatment efficacy. Additionally, Proteome Sciences licenses its proprietary biomarker technologies and assays to biotech and pharmaceutical companies, which contributes to its revenue streams. The company's earnings are also supported by strategic partnerships and collaborations within the life sciences industry, enabling it to expand its service offerings and reach.

Proteome Sciences Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
10.87B	5.03M	23.74B	22.59B	16.95B	19.73B
	Gross Profit
10.87B	1.65M	23.73B	22.59B	16.94B	19.73B
	EBIT
2.74B	-1.62M	8.66B	9.03B	3.51B	6.31B
	EBITDA
-2.54M	-1.14M	1.83M	625.00K	714.00K	388.00K
	Net Income Common Stockholders
-4.08M	-2.44M	1.32M	72.00K	295.00K	149.00K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
180.03B	2.03M	252.89B	240.31B	193.69B	153.39B
	Total Assets
1.13T	11.46M	1.51T	1.38T	1.35T	1.14T
	Total Debt
127.18B	13.47M	139.92B	138.58B	120.95B	128.01B
	Net Debt
-52.84B	11.45M	-112.98B	-101.73B	-72.74B	-25.37B
	Total Liabilities
1.07T	14.52M	1.44T	1.31T	1.28T	1.07T
	Stockholders Equity
62.56B	-3.07M	68.29B	69.05B	65.80B	64.43B
Cash Flow		Free Cash Flow
-10.68B	-718.00K	2.14B	8.80B	-9.07B	-23.24B
	Operating Cash Flow
-8.96B	-481.00K	3.88B	10.52B	-7.74B	-21.45B
	Investing Cash Flow
-8.63B	-424.00K	-21.67B	4.27B	-18.38B	-23.96B
	Financing Cash Flow
-17.08B	-1.06M	27.05B	38.50B	67.98B	21.64B

Proteome Sciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRM, the sentiment is Neutral. The current price of 3.26 is above the 20-day moving average (MA) of 2.95, below the 50-day MA of 3.54, and below the 200-day MA of 3.40, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 52.04 is Neutral, neither overbought nor oversold. The STOCH value of 66.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:PRM.

Proteome Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IXI	53 Neutral	£8.57M	―	-19.15%	―	-13.49%	-69.67%
Sector *	52 Neutral	$5.04B	3.15	-44.58%	2.85%	16.08%	-0.27%
GDR	52 Neutral	£8.71M	―	-321.90%	―	125.37%	22.47%
ABDX	52 Neutral	£11.81M	―	-62.83%	―	27.60%	1.35%
OBD	44 Neutral	£7.83M	―	-222.16%	―	24.71%	38.28%
PRM	33 Underperform	£9.62M	―		―	-2.80%	-38.55%

Proteome Sciences Corporate Events

Proteome Sciences Sees Strong Recovery and Growth Prospects

At its Annual General Meeting, Proteome Sciences announced a continued recovery in the pharmaceutical and biotech markets, with a strong pipeline of orders extending into 2026. The company is progressing with licensing discussions for new DXT tags and has completed its first commercial single cell proteomics project. The increased demand has led to full capacity utilization at their Frankfurt site, positioning the company for substantial future revenue growth.

Spark’s Take on GB:PRM Stock

According to Spark, TipRanks’ AI Analyst, GB:PRM is a Underperform.

Proteome Sciences faces significant financial instability with negative equity, declining revenues, and cash flow difficulties. These factors strongly weigh down the stock score. Although recent corporate events show promise and potential future growth, the current financial challenges and weak technical indicators overshadow these positive developments.

To see Spark’s full report on GB:PRM stock, click here.

Proteome Sciences Reports 2024 Financial Results Amid Market Recovery

Proteome Sciences reported its final results for 2024, highlighting a total revenue of £4.89 million, a slight decrease from the previous year. Despite a challenging start due to the global downturn in biotech and pharma markets, the company saw a strong recovery in the second half of 2024, driven by increased customer orders and the launch of new products like TMTpro 35 plex tags. The company secured significant contracts, including a GCLP contract with a US biopharmaceutical company, and expanded its service offerings with data-independent acquisition and single-cell proteomics. Looking forward, Proteome Sciences anticipates substantial growth, with a robust order pipeline extending into 2026, supported by investments in new laboratory facilities and equipment.

Proteome Sciences to Announce 2024 Financial Results and Host Investor Presentation

Proteome Sciences announced that it will release its financial results for the year ending 31 December 2024 on 10 April 2025. The company will host a live presentation on 11 April 2025, led by Executive Chairman Christopher Pearce and Chief Scientific Officer Dr. Ian Pike, to discuss the results and outlook for 2025. This presentation is accessible to all existing and potential shareholders, allowing them to submit questions in advance or during the event. This announcement is significant as it provides stakeholders with insights into the company’s performance and future plans, potentially impacting investor confidence and market positioning.

Proteome Sciences Secures Major Contract with US Biopharma

Proteome Sciences has secured a significant contract with a US biopharmaceutical company to provide mass spectrometry services for a clinical trial, valued at over $1 million. This agreement, which utilizes their GCLP accreditation, is expected to be largely fulfilled within the current financial year and into 2026, demonstrating the company’s growing demand in the US and Europe for its specialized services.